₹214.31
−0.85%NSE close, 16 Nov 2026
−0.80%
Jagsonpal Pharmaceuticals is a small cap company, listed on NSE under the symbol JAGSNPHARM. At ₹214.31 a share, the market values the whole company at ₹1,414 crore.
In FY26, it reported sales of ₹287 crore and a net profit of ₹43 crore, an operating margin of 20.2%. Over the last three years, sales grew 8.3% a year and net profit grew 30.0% a year.
The market values the company at 31.3 times its profit over the last twelve months and 5.87 times its book value; its return on equity is 18.8% and it has almost no borrowings.
Promoters hold 68.81% of the shares. Foreign institutions hold 2.14%, and domestic institutions, mutual funds among them, 1.65%.
Over the past year the share price has fallen 1.1%, and it is 19.0% below its 52-week high.
₹ crore. Consolidated figures where the company filed them, standalone otherwise (marked S).
| Line | Dec 2023 S | Mar 2024 S | Jun 2024 S | Sep 2024 S | Dec 2024 S | Mar 2025 S | Jun 2025 S | Sep 2025 S |
|---|
Transcript
Link of Recording
Press Release for Unaudited Financial Results for quarter and half year ended September 30, 2026
Presentation
| Dec 2025 S |
|---|
| Mar 2026 S |
|---|
| Jun 2026 S |
|---|
| Sep 2026 |
|---|
| Sales | 47.2 | 43.5 | 61.4 | 74.7 | 74.0 | 58.6 | 75.6 | 74.5 | 72.9 | 64.2 | 82.2 | 96.4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Expenses | 43.8 | 40.8 | 51.2 | 58.4 | 58.2 | 49.9 | 61.4 | 58.0 | 56.7 | 53.0 | 65.0 | 79.5 |
| Operating profit | 3.4 | 2.7 | 10.2 | 16.3 | 15.8 | 8.7 | 14.2 | 16.4 | 16.3 | 11.2 | 17.2 | 16.9 |
| Operating margin | 7.2% | 6.1% | 16.7% | 21.8% | 21.4% | 14.9% | 18.8% | 22.1% | 22.3% | 17.4% | 21.0% | 17.5% |
| Other income | 2.5 | 2.5 | 1.4 | 1.7 | 2.3 | 2.8 | 2.8 | 3.0 | 3.0 | 3.2 | 2.8 | 2.3 |
| Interest | 0.2 | 0.2 | 0.2 | 0.2 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 |
| Depreciation | 0.4 | 0.4 | 1.1 | 2.3 | 2.4 | 2.3 | 2.4 | 2.4 | 2.4 | 2.3 | 2.1 | 2.2 |
| Profit before tax | 5.3 | 4.5 | 7.1 | 15.4 | 38.7 | 8.7 | 14.4 | 16.8 | 14.5 | 11.8 | 17.7 | 16.4 |
| Tax | 1.3 | 1.0 | 1.8 | 3.9 | 6.7 | 2.1 | 3.6 | 4.2 | 3.6 | 3.0 | 4.5 | 4.1 |
| Net profit | 4.0 | 3.6 | 5.3 | 11.5 | 32.0 | 6.6 | 10.8 | 12.6 | 11.0 | 8.8 | 13.2 | 12.3 |
| EPS (₹) | 1.48 | 1.31 | 1.94 | 4.29 | 4.74 | 0.98 | 1.60 | 1.88 | 1.67 | 1.25 | 2.00 | 1.86 |
₹ crore, financial years to March.
| Line | FY19 S | FY20 S | FY21 S | FY22 S | FY23 S | FY25 S | FY26 S |
|---|---|---|---|---|---|---|---|
| Sales | 167 | 159 | 188 | 226 | 237 | 269 | 287 |
| Expenses | 157 | 150 | 169 | 200 | 203 | 218 | 229 |
| Operating profit | 9.3 | 8.5 | 19.1 | 25.8 | 33.4 | 51.1 | 58.1 |
| Operating margin | 5.6% | 5.4% | 10.2% | 11.4% | 14.1% | 19.0% | 20.2% |
| Other income | 1.4 | 2.5 | 4.4 | 3.3 | 5.7 | 8.2 | 12.0 |
| Interest | 0.8 | 0.5 | 0.5 | 0.3 | 0.4 | 1.0 | 1.0 |
| Depreciation | 1.0 | 1.1 | 1.1 | 1.5 | 1.2 | 8.1 | 9.4 |
| Profit before tax | 9.0 | 9.4 | 21.9 | 27.3 | 31.7 | 69.9 | 57.5 |
| Tax | 1.8 | 1.5 | 4.8 | 7.7 | 7.5 | 14.5 | 14.4 |
| Net profit | 7.2 | 7.9 | 17.1 | 19.6 | 24.2 | 55.4 | 43.1 |
| EPS (₹) | 2.75 | 3.00 | 6.51 | 7.48 | 9.22 | 8.26 | 6.40 |
₹ crore, at each year's end and the latest half year.
₹ crore, by financial year, and the latest half year.
| Line | FY22 | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|---|
| From operations | 5.6 | 55.3 | 46.8 | 25.5 |
| From investing | −26.2 | −45.2 | −35.7 | 45.5 |
| From financing | −12.3 | −11.7 | −12.2 | −62.0 |
| Spent on fixed assets | −0.5 | −0.4 | 0 | 0 |
| Free cash flow | 5.1 | 54.9 | 46.8 | 25.5 |
Margins, returns, debt, tax and cash.
| Line | FY19 | FY20 | FY21 | FY22 | FY23 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| Net margin | 4.3% | 5.0% | 9.1% | 8.7% | 10.2% | 20.6% | 15.0% |
| Operating margin | 5.6% | 5.4% | 10.2% | 11.4% | 14.1% | 19.0% | 20.2% |
| Return on equity | – | – | – | – | 15.2% | 23.1% | 15.6% |
| Return on capital employed | – | – | – | – | 20.2% | 29.5% | 21.2% |
| Return on assets | – | – | – | – | 12.4% | 19.9% | 13.6% |
| Debt to equity | – | – | – | – | 0.00 | 0.00 | 0.00 |
| Interest coverage | 13.00 | 19.50 | 43.90 | 95.20 | 76.50 | 73.80 | 56.80 |
| Debt to assets | – | – | – | – | 0.00 | 0.00 | 0.00 |
| Current ratio | – | – | – | – | 5.97 | 6.22 | 5.06 |
| Quick ratio | – | – | – | – | 5.22 | 5.64 | 4.54 |
| Cash ratio | – | – | – | – | 0.40 | 0.43 | 0.35 |
| Asset turnover | – | – | – | – | 1.21 | 0.97 | 0.91 |
| Fixed asset turnover | – | – | – | – | 12.90 | 440.52 | 503.91 |
| Inventory turnover | – | – | – | – | – | 6.30 | 7.10 |
| Receivables turnover | – | – | – | – | 11.30 | 20.40 | 16.70 |
| Gross margin | – | – | – | – | – | 64.1% | 63.7% |
| Cash from operations to profit | – | – | – | 29.0% | – | 100.0% | 109.0% |
| Effective tax rate | 19.9% | 16.4% | 22.0% | 28.3% | 23.8% | 20.8% | 25.1% |
The financial results for the period ended September 30, 2026.
Subsequent to fulfilment of the Conditions Precedent under the BTA the transaction has been consummated with effect from today i.e., October 01, 2026.
Allotment of 101825 Equity Shares under the Jagsonpal Pharmaceuticals Limited Employee stock option Plan 2022
Press Release on Acquisition of the wellness portfolio of group Pharmaceuticals Limited
The Acquisition of Wellness Portfolio of Group Pharmaceuticals Limited.
A copy Srutinizers report of Annual General Meeting held on September 18, 2026. Further, the company has informed the Exchange regarding voting results.
Notice of Annual General Meeting to be held on September 18, 2026
Providing a web-link of the Annual Report 2025-26 to members
Allotment of 27950 Equity Shares under the Jagsonpal Pharmaceuticals Limited Employee Stock Option Plan, 2022
Transcript